NAMS Menopause Certification Exam 2026/2027
Actual Exam 2026/2027 | Complete Exam-Style
Questions with Detailed Rationales | 100% Verified
– Pass Guaranteed – A+ Graded
VERSION 1
Physiology & Pathophysiology of Menopause Transition
Q1: According to the STRAW+10 staging system, which menstrual criterion defines entry
into the early menopause transition (stage −2)?
A. Cycles that remain perfectly regular with no change in length
B. A persistent difference of ≥7 days in the length of consecutive cycles [CORRECT]
C. At least 12 months of amenorrhea
D. Two or more skipped cycles with a ≥60-day amenorrhea interval
Correct Answer: B
Rationale: This matches the principle that stage −2 begins when consecutive cycle lengths
differ by 7 days or more, sustained over time. The 60-day amenorrhea marker belongs to
stage −1, and 12 months of amenorrhea defines menopause itself.
Q2: A 47-year-old woman reports her cycles were 24 days, then 31 days, then 23 days over
the past 3 months, with no skipped periods. Using STRAW+10, which stage best describes
her?
A. Peak reproductive (stage −4)
B. Late reproductive (stage −3b)
C. Early menopause transition (stage −2) [CORRECT]
D. Late menopause transition (stage −1)
Correct Answer: C
Rationale: The best answer is early menopause transition, since her consecutive cycles vary
by 7 days or more without the 60-day amenorrhea required for stage −1. Subtle shortening
with regularity would still be late reproductive.
Q3: The hallmark menstrual criterion of the late menopause transition (stage −1) is:
A. Cycle length variation of 3–5 days
B. An interval of amenorrhea of at least 60 days [CORRECT]
C. Persistent intermenstrual spotting
D. Regular cycles with elevated FSH on every draw
Correct Answer: B
Rationale: This choice is correct because ≥60 days of amenorrhea, reflecting at least two
skipped cycles, defines stage −1. Cycle variation of only a few days does not move a woman
out of the reproductive stages.
,Q4: A 52-year-old woman presents after 13 months without a period. FSH is 58 mIU/mL and
estradiol is 15 pg/mL. What is the appropriate interpretation?
A. She is postmenopausal, and the clinical history alone is sufficient diagnosis [CORRECT]
B. She needs an estradiol level repeated monthly for confirmation
C. She requires an endometrial biopsy before any diagnosis is made
D. She should be labeled perimenopausal until FSH exceeds 100 mIU/mL
Correct Answer: A
Rationale: After 12 months of amenorrhea, menopause is a retrospective clinical diagnosis,
and her hormone values are entirely consistent with it. No fixed FSH threshold confirms
menopause, and repeat monthly testing adds nothing.
Q5: Why does FSH rise so dramatically during the menopause transition?
A. The pituitary becomes hypersensitive to estradiol
B. Declining follicle number reduces inhibin B and estradiol, removing negative feedback on
FSH [CORRECT]
C. FSH clearance slows with aging kidneys
D. The hypothalamus increases GnRH pulse frequency only after menopause
Correct Answer: B
Rationale: The clinical pearl here is that inhibin B from smaller follicles is the earliest
feedback lost, so FSH climbs even while estradiol is still fluctuating. It is a follicle-depletion
story, not a pituitary or renal one.
Q6: Which estradiol level is most typical of a woman who is fully postmenopausal?
A. 50–100 pg/mL
B. 100–200 pg/mL
C. Below 20 pg/mL [CORRECT]
D. 200–300 pg/mL
Correct Answer: C
Rationale: Ovarian estradiol production falls to generally below 20 pg/mL after menopause.
Mid-range values like 50–200 pg/mL suggest ongoing follicular activity, which would be
expected in perimenopause, not after it.
Q7: A 49-year-old with irregular cycles reports breast tenderness and bloating. FSH is 42
mIU/mL but estradiol is 245 pg/mL. What best explains these findings?
A. Lab error requiring repeat testing
B. A luteal out-of-phase (LOOP) event with transient supraphysiologic estrogen [CORRECT]
C. Early pregnancy with a nonviable gestation
D. An estrogen-secreting ovarian tumor
Correct Answer: B
Rationale: This aligns with the luteal out-of-phase event, where a follicle is recruited against
an elevated FSH backdrop and produces very high estradiol without a proper progesterone
rise. These transient estrogen surges are common in perimenopause and do not mean she is
close to her final period — contraception still matters.
Q8: A 32-year-old has had 7 months of amenorrhea and two FSH values of 46–52 mIU/mL.
What is the best next step?
A. Reassure and recheck FSH in 12 months
,B. Begin combined hormonal contraception for cycle control
C. Evaluate for primary ovarian insufficiency and plan hormone therapy until about age 51
[CORRECT]
D. Start raloxifene for anticipated bone loss
Correct Answer: C
Rationale: The best answer is a full POI evaluation — including karyotype, FMR1, and
autoimmune screening — paired with systemic hormone therapy continued to the average
age of natural menopause. Waiting or using contraception-as-treatment leaves her bones,
heart, and brain estrogen-deprived for decades.
Q9: Primary ovarian insufficiency is most commonly associated with which autoimmune
condition?
A. Celiac disease
B. Type 1 diabetes
C. Autoimmune thyroid disease [CORRECT]
D. Autoimmune hepatitis
Correct Answer: C
Rationale: This matches the principle that thyroid autoimmunity is the most frequent
autoimmune association in POI, which is why TSH and thyroid antibodies belong in the
workup. Adrenal antibodies are less common but critically important to check because of
Addison disease risk.
Q10: A healthy 43-year-old has gone 14 months without a period. What is the appropriate
long-term plan?
A. Observe without therapy until age 51
B. Offer systemic hormone therapy until roughly the average age of natural menopause,
absent contraindications [CORRECT]
C. Prescribe low-dose vaginal estrogen only
D. Begin bisphosphonate therapy as first-line protection
Correct Answer: B
Rationale: Early menopause deprives her of estrogen for many years, so The Menopause
Society recommends systemic HT at least until the average age of menopause, around 51,
unless a contraindication exists. Vaginal estrogen alone or a bisphosphonate as first-line
therapy does not address her vasomotor and systemic risks.
Q11: What is the core thermoregulatory problem driving vasomotor symptoms?
A. An elevated metabolic rate after estrogen loss
B. Narrowing of the hypothalamic thermoneutral zone, so tiny core temperature shifts
trigger heat-dissipation responses [CORRECT]
C. Peripheral vasodilation from elevated progesterone
D. Loss of sweat gland function with aging
Correct Answer: B
Rationale: The clinical pearl here is that estrogen decline narrows the thermoneutral zone,
so trivial core temperature changes launch flushing, sweating, and chills. This is why
nonhormonal drugs acting on hypothalamic KNDy neurons, like fezolinetant, can reduce
flushes.
, Q12: A 44-year-old underwent total hysterectomy with bilateral salpingo-oophorectomy for
endometriosis and now has severe hot flashes. What is the best approach?
A. Withhold all hormones because she is high-risk after surgery
B. Offer systemic estrogen therapy, planned until around age 51 [CORRECT]
C. Provide vaginal estrogen monotherapy indefinitely
D. Recommend black cohosh as primary treatment
Correct Answer: B
Rationale: This aligns with the strong evidence that surgical menopause causes abrupt, often
severe symptoms and higher bone and cardiovascular risk, so systemic estrogen until the
average menopause age is appropriate. Vaginal estrogen will not touch her vasomotor
symptoms.
Q13: Regarding ovarian follicle depletion across the lifespan, which statement is accurate?
A. Roughly 1–2 million follicles at birth decline to about 1,000 near menopause [CORRECT]
B. New follicles are recruited from stem cells in midlife
C. Follicle numbers remain stable until the final menstrual period, then fall suddenly
D. Fewer than 100 follicles remain at birth
Correct Answer: A
Rationale: This choice is correct because follicles peak in utero, fall to 1–2 million at birth,
and drop to roughly a thousand around menopause, with depletion accelerating in the late
transition. There is no meaningful follicular regeneration in humans.
Q14: A 50-year-old using a progestin-only pill asks whether her undetectable AMH proves
she is menopausal. What is the best response?
A. Yes, undetectable AMH is diagnostic of menopause at any age
B. No — hormonal contraception alters interpretation, and AMH alone cannot stage
menopause [CORRECT]
C. Yes, but only if FSH is also above 10 mIU/mL
D. No, because AMH rises after menopause
Correct Answer: B
Rationale: Remember, AMH declines gradually and becomes unmeasurable near the final
menstrual period, but it is a supportive marker only — and hormonal contraception makes
both AMH and FSH hard to interpret for staging.
Q15: A 51-year-old on a progestin-only pill has had no bleeding for 16 months and wants to
know if she has reached menopause. What should you tell her?
A. Sixteen months of amenorrhea means she has completed menopause
B. You cannot use amenorrhea to diagnose menopause while she takes hormonal
contraception [CORRECT]
C. A single FSH of 25 mIU/mL on the pill would confirm menopause
D. She should stop the pill immediately to let a period occur
Correct Answer: B
Rationale: This matches the principle that hormonal contraception suppresses the
menstrual and endocrine markers used for staging, so menopause cannot be confirmed on
them. She should continue contraception, typically to age 55, since ovulation can still
resume.
Actual Exam 2026/2027 | Complete Exam-Style
Questions with Detailed Rationales | 100% Verified
– Pass Guaranteed – A+ Graded
VERSION 1
Physiology & Pathophysiology of Menopause Transition
Q1: According to the STRAW+10 staging system, which menstrual criterion defines entry
into the early menopause transition (stage −2)?
A. Cycles that remain perfectly regular with no change in length
B. A persistent difference of ≥7 days in the length of consecutive cycles [CORRECT]
C. At least 12 months of amenorrhea
D. Two or more skipped cycles with a ≥60-day amenorrhea interval
Correct Answer: B
Rationale: This matches the principle that stage −2 begins when consecutive cycle lengths
differ by 7 days or more, sustained over time. The 60-day amenorrhea marker belongs to
stage −1, and 12 months of amenorrhea defines menopause itself.
Q2: A 47-year-old woman reports her cycles were 24 days, then 31 days, then 23 days over
the past 3 months, with no skipped periods. Using STRAW+10, which stage best describes
her?
A. Peak reproductive (stage −4)
B. Late reproductive (stage −3b)
C. Early menopause transition (stage −2) [CORRECT]
D. Late menopause transition (stage −1)
Correct Answer: C
Rationale: The best answer is early menopause transition, since her consecutive cycles vary
by 7 days or more without the 60-day amenorrhea required for stage −1. Subtle shortening
with regularity would still be late reproductive.
Q3: The hallmark menstrual criterion of the late menopause transition (stage −1) is:
A. Cycle length variation of 3–5 days
B. An interval of amenorrhea of at least 60 days [CORRECT]
C. Persistent intermenstrual spotting
D. Regular cycles with elevated FSH on every draw
Correct Answer: B
Rationale: This choice is correct because ≥60 days of amenorrhea, reflecting at least two
skipped cycles, defines stage −1. Cycle variation of only a few days does not move a woman
out of the reproductive stages.
,Q4: A 52-year-old woman presents after 13 months without a period. FSH is 58 mIU/mL and
estradiol is 15 pg/mL. What is the appropriate interpretation?
A. She is postmenopausal, and the clinical history alone is sufficient diagnosis [CORRECT]
B. She needs an estradiol level repeated monthly for confirmation
C. She requires an endometrial biopsy before any diagnosis is made
D. She should be labeled perimenopausal until FSH exceeds 100 mIU/mL
Correct Answer: A
Rationale: After 12 months of amenorrhea, menopause is a retrospective clinical diagnosis,
and her hormone values are entirely consistent with it. No fixed FSH threshold confirms
menopause, and repeat monthly testing adds nothing.
Q5: Why does FSH rise so dramatically during the menopause transition?
A. The pituitary becomes hypersensitive to estradiol
B. Declining follicle number reduces inhibin B and estradiol, removing negative feedback on
FSH [CORRECT]
C. FSH clearance slows with aging kidneys
D. The hypothalamus increases GnRH pulse frequency only after menopause
Correct Answer: B
Rationale: The clinical pearl here is that inhibin B from smaller follicles is the earliest
feedback lost, so FSH climbs even while estradiol is still fluctuating. It is a follicle-depletion
story, not a pituitary or renal one.
Q6: Which estradiol level is most typical of a woman who is fully postmenopausal?
A. 50–100 pg/mL
B. 100–200 pg/mL
C. Below 20 pg/mL [CORRECT]
D. 200–300 pg/mL
Correct Answer: C
Rationale: Ovarian estradiol production falls to generally below 20 pg/mL after menopause.
Mid-range values like 50–200 pg/mL suggest ongoing follicular activity, which would be
expected in perimenopause, not after it.
Q7: A 49-year-old with irregular cycles reports breast tenderness and bloating. FSH is 42
mIU/mL but estradiol is 245 pg/mL. What best explains these findings?
A. Lab error requiring repeat testing
B. A luteal out-of-phase (LOOP) event with transient supraphysiologic estrogen [CORRECT]
C. Early pregnancy with a nonviable gestation
D. An estrogen-secreting ovarian tumor
Correct Answer: B
Rationale: This aligns with the luteal out-of-phase event, where a follicle is recruited against
an elevated FSH backdrop and produces very high estradiol without a proper progesterone
rise. These transient estrogen surges are common in perimenopause and do not mean she is
close to her final period — contraception still matters.
Q8: A 32-year-old has had 7 months of amenorrhea and two FSH values of 46–52 mIU/mL.
What is the best next step?
A. Reassure and recheck FSH in 12 months
,B. Begin combined hormonal contraception for cycle control
C. Evaluate for primary ovarian insufficiency and plan hormone therapy until about age 51
[CORRECT]
D. Start raloxifene for anticipated bone loss
Correct Answer: C
Rationale: The best answer is a full POI evaluation — including karyotype, FMR1, and
autoimmune screening — paired with systemic hormone therapy continued to the average
age of natural menopause. Waiting or using contraception-as-treatment leaves her bones,
heart, and brain estrogen-deprived for decades.
Q9: Primary ovarian insufficiency is most commonly associated with which autoimmune
condition?
A. Celiac disease
B. Type 1 diabetes
C. Autoimmune thyroid disease [CORRECT]
D. Autoimmune hepatitis
Correct Answer: C
Rationale: This matches the principle that thyroid autoimmunity is the most frequent
autoimmune association in POI, which is why TSH and thyroid antibodies belong in the
workup. Adrenal antibodies are less common but critically important to check because of
Addison disease risk.
Q10: A healthy 43-year-old has gone 14 months without a period. What is the appropriate
long-term plan?
A. Observe without therapy until age 51
B. Offer systemic hormone therapy until roughly the average age of natural menopause,
absent contraindications [CORRECT]
C. Prescribe low-dose vaginal estrogen only
D. Begin bisphosphonate therapy as first-line protection
Correct Answer: B
Rationale: Early menopause deprives her of estrogen for many years, so The Menopause
Society recommends systemic HT at least until the average age of menopause, around 51,
unless a contraindication exists. Vaginal estrogen alone or a bisphosphonate as first-line
therapy does not address her vasomotor and systemic risks.
Q11: What is the core thermoregulatory problem driving vasomotor symptoms?
A. An elevated metabolic rate after estrogen loss
B. Narrowing of the hypothalamic thermoneutral zone, so tiny core temperature shifts
trigger heat-dissipation responses [CORRECT]
C. Peripheral vasodilation from elevated progesterone
D. Loss of sweat gland function with aging
Correct Answer: B
Rationale: The clinical pearl here is that estrogen decline narrows the thermoneutral zone,
so trivial core temperature changes launch flushing, sweating, and chills. This is why
nonhormonal drugs acting on hypothalamic KNDy neurons, like fezolinetant, can reduce
flushes.
, Q12: A 44-year-old underwent total hysterectomy with bilateral salpingo-oophorectomy for
endometriosis and now has severe hot flashes. What is the best approach?
A. Withhold all hormones because she is high-risk after surgery
B. Offer systemic estrogen therapy, planned until around age 51 [CORRECT]
C. Provide vaginal estrogen monotherapy indefinitely
D. Recommend black cohosh as primary treatment
Correct Answer: B
Rationale: This aligns with the strong evidence that surgical menopause causes abrupt, often
severe symptoms and higher bone and cardiovascular risk, so systemic estrogen until the
average menopause age is appropriate. Vaginal estrogen will not touch her vasomotor
symptoms.
Q13: Regarding ovarian follicle depletion across the lifespan, which statement is accurate?
A. Roughly 1–2 million follicles at birth decline to about 1,000 near menopause [CORRECT]
B. New follicles are recruited from stem cells in midlife
C. Follicle numbers remain stable until the final menstrual period, then fall suddenly
D. Fewer than 100 follicles remain at birth
Correct Answer: A
Rationale: This choice is correct because follicles peak in utero, fall to 1–2 million at birth,
and drop to roughly a thousand around menopause, with depletion accelerating in the late
transition. There is no meaningful follicular regeneration in humans.
Q14: A 50-year-old using a progestin-only pill asks whether her undetectable AMH proves
she is menopausal. What is the best response?
A. Yes, undetectable AMH is diagnostic of menopause at any age
B. No — hormonal contraception alters interpretation, and AMH alone cannot stage
menopause [CORRECT]
C. Yes, but only if FSH is also above 10 mIU/mL
D. No, because AMH rises after menopause
Correct Answer: B
Rationale: Remember, AMH declines gradually and becomes unmeasurable near the final
menstrual period, but it is a supportive marker only — and hormonal contraception makes
both AMH and FSH hard to interpret for staging.
Q15: A 51-year-old on a progestin-only pill has had no bleeding for 16 months and wants to
know if she has reached menopause. What should you tell her?
A. Sixteen months of amenorrhea means she has completed menopause
B. You cannot use amenorrhea to diagnose menopause while she takes hormonal
contraception [CORRECT]
C. A single FSH of 25 mIU/mL on the pill would confirm menopause
D. She should stop the pill immediately to let a period occur
Correct Answer: B
Rationale: This matches the principle that hormonal contraception suppresses the
menstrual and endocrine markers used for staging, so menopause cannot be confirmed on
them. She should continue contraception, typically to age 55, since ovulation can still
resume.
